Sustained ventricular tachycardia in acute coronary syndromes the Portuguese experience

Abstract

Abstract Funding Acknowledgements Type of funding sources: None. OnBehalf Portuguese Registry of Acute Coronary Syndromes Background Acute coronary syndromes (ACS) are frequent and are associated with high levels of comorbidities and complications. Ventricular tachycardia (VT) is one of the most danger and stressful situations in ACS. Objective Evaluate predictors of ventricular tachycardia in ACS. Methods Multicenter retrospective study, based on the Portuguese Registry of ACS between 1/10/2010-4/09/2019. Patients were divided in two groups: A – patients without VT, and B – patients that presented VT on the hospitalization. VT was defined as a register or more of the VT with at least 30 seconds. Logistic regression was performed to assess predictors of VT in ACS patients. Results 25361 in group A (98.6%) and 364 in group B (1.4%). Both groups were similar regarding gender, cardiovascular risk factors, except for dyslipidemia (61.7 vs 51.9%, p < 0.001) and ST-segment elevation myocardial infarction (STEMI) location. Group B was elderly (67 ± 14 vs 70 ± 14, p < 0.001), was admitted directly to the cat lab (10.6 vs 20.4%, p < 0.001), had less time since the onset of symptoms until the admission (383 ± 157 vs 349 ± 121, p = 0.003), but presented higher previous history of heart failure (5.9 vs 10.6%, p < 0.001), peripheral vascular disease (5.5 vs 8.4%, p = 0.015), chronic obstructive pulmonary disease (COPD) (4.4 vs 7.9%, p = 0.001) and dementia (1.7 vs 3.2%, p = 0.038). At admission presented higher levels of STEMI (42 vs 67%, p < 0.001), dyspnea (29 vs 18.1%, p < 0.001), syncope (1.3 vs 6.6%, p < 0.001), cardiac arrest (0.4 vs 4.4%, p < 0.001), Killip-Kimball classification > I (14.8 vs 40.5%, p < 0.001) and atrial fibrillation at admission (AF) (7.1 vs 15.3%, p < 0.001). Ivabradine (3.7 vs 7.6%, p < 0.001), aldosterone receptor antagonists (10.2 vs 24%, p < 0.001), diuretic (28 vs 57.2%, p < 0.001), amiodarone (5.6 vs 53.5%, p < 0.001), digoxin (1.4 vs 4.7%, p < 0.001) were more prevalent used in the admission. Group B exhibited higher multivessel disease (MVD) (51.5 vs 61.5%, p < 0.001), culprit as common coronary trunk (CT) (1.7 vs 4.2%, p = 0.024), hybrid revascularization (0.8 vs 2%, p = 0.032) and left ventricular ejection fraction (LVEF)<50% (38.7 vs 71%, p < 0.001). On the other hand, the used of beta block (81.4 vs 62.3%, p < 0.001), angiotensin-converting-enzyme inhibitor (85.5 vs 74.4%, p < 0.001) and calcium channel blockers (10.1 vs 24%, p < 0.001) since had a protect effect. Regarding reinfarction (0.9 vs 2.5%, p = 0.007), de novo heart failure (15.1 vs 50.3%, p < 0.001), atrioventricular block (2.2 vs 17%, p < 0.001), stroke (1.4 vs 4.9%, p < 0.001) and death (3.4 vs 26.9%, p < 0.001), all were higher in Group B. Logistic regression revealed COPD (odds ratio (OR) 1.9, p = 0.010, confidence interval (CI) 1.17-3.10), STEMI (OR 2.73, p < 0.001, CI 2.00-3.73), AF (OR 2.30, p < 0.001, CI 1.52-3.49), MVD (OR 1.44, p = 0.012, CI 1.08-1.92), CT (OR 2.87, p = 0.003, CI 1.45-5.69) and LVEF < 50% (OR 3.44, p < 0.001, CI 2.52-4.71) as predictors of VT in ACS. Conclusions COPD, STEMI, AF, MVD, CT and LVEF < 50% were predictors of VT in ACS.